Literature DB >> 15539513

Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.

Jo Southern1, Sarah Deane, Lindsey Ashton, Ray Borrow, David Goldblatt, Nick Andrews, Paul Balmer, Rhonwen Morris, J Simon Kroll, Elizabeth Miller.   

Abstract

Extensive use of meningococcal AC polysaccharide (MACP) vaccines has raised concerns about induction of immunologic hyporesponsiveness to C polysaccharide. We investigated the immunogenicity and safety of a meningococcal C-tetanus conjugate (MCC-TT) vaccine in naive adults and prior MACP vaccinees. Laboratory staff (n = 113) were recruited; 73 were naive to meningococcal vaccination, and 40 had previously received > or =1 dose of MACP vaccine. Blood was taken prior to MCC-TT vaccination and 1 week, 1 month, and 6 months later. At each time point, proportions of subjects with serum bactericidal antibody (SBA) titers of > or =8 or > or =128 were similar (P > 0.46); >94% of subjects achieved titers of > or =128 at 1 month. However, the geometric mean titer (GMT) of SBA at 1 month was higher in the naive (1,757; 95% confidence interval [95% CI], 1,102 to 2,803) than in the previously vaccinated (662; 95% CI, 363 to 1,207) group (P = 0.02), and similarly at 6 months (P < 0.001). Conversely, geometric mean concentrations (GMCs) of serogroup C-specific immunoglobulin G (IgG) were significantly higher in the previously vaccinated group pre-MCC-TT and at 1 week; the groups were similar at 1 month, and there was some evidence that the GMC for the previously vaccinated group was higher at 6 months. Qualitative differences in antibodies between groups were demonstrated by using the SBA/IgG ratio, though avidity measures were similar for the two groups throughout the study. MCC-TT was well tolerated, with similar safety profiles in the two groups. Pain in the arm and headache were the most frequently reported events following vaccination. The study shows that MCC-TT is safe and immunogenic in naive and previously MACP-vaccinated adults, though the magnitude and persistence of postvaccination SBA responses in the latter group were lower.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539513      PMCID: PMC524764          DOI: 10.1128/CDLI.11.6.1100-1104.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  22 in total

1.  Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.

Authors:  P Richmond; R Borrow; E Miller; S Clark; F Sadler; A Fox; N Begg; R Morris; K Cartwright
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

2.  [Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine dTpa) in 10 to 11 years old children and in adults].

Authors:  Katia Abarca; Francisca Valdivieso; Marcela Potin; Isabel Ibáñez; Pablo Vial
Journal:  Rev Med Chil       Date:  2002-05       Impact factor: 0.553

3.  Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.

Authors:  R Borrow; D Goldblatt; N Andrews; P Richmond; J Southern; E Miller
Journal:  J Infect Dis       Date:  2001-07-10       Impact factor: 5.226

4.  Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults.

Authors:  David Goldblatt; Ray Borrow; Elizabeth Miller
Journal:  J Infect Dis       Date:  2002-01-10       Impact factor: 5.226

5.  Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls.

Authors:  R Borrow; J Southern; N Andrews; N Peake; R Rahim; M Acuna; S Martin; E Miller; E Kaczmarski
Journal:  Vaccine       Date:  2001-04-30       Impact factor: 3.641

6.  Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults.

Authors:  P Richmond; D Goldblatt; P C Fusco; J D Fusco; I Heron; S Clark; R Borrow; F Michon
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

7.  Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.

Authors:  P Richmond; R Borrow; J Findlow; S Martin; C Thornton; K Cartwright; E Miller
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

Authors:  P Richmond; R Borrow; D Goldblatt; J Findlow; S Martin; R Morris; K Cartwright; E Miller
Journal:  J Infect Dis       Date:  2000-11-14       Impact factor: 5.226

9.  Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.

Authors:  E Miller; D Salisbury; M Ramsay
Journal:  Vaccine       Date:  2001-10-15       Impact factor: 3.641

10.  Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Authors:  R Borrow; N Andrews; D Goldblatt; E Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

View more
  13 in total

1.  Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients.

Authors:  A Meerveld-Eggink; O de Weerdt; R M de Voer; G A M Berbers; H van Velzen-Blad; B J Vlaminckx; D H Biesma; G T Rijkers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-24       Impact factor: 3.267

Review 2.  When should vaccination be contraindicated in children?

Authors:  Laura Lane; Arlene Reynolds; Mary Ramsay
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Anti-pneumococcal antibody titre measurement: what useful information does it yield?

Authors:  Paul Balmer; Andrew J Cant; Ray Borrow
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

4.  Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.

Authors:  Helen Findlow; Samba Sow; Ray Borrow; Milagritos Tapia; Fadima Cheick Haidara; Adebayo K Akinsola; Olubukola T Idoko; Fatoumata Diallo; Richard Adegbola; Yuxiao Tang; Varsha Parulekar; Helen Chadha; Lesley Mabey; Daniel Holme; Kelly Townsend; Julie Chaumont; F Marc Laforce; Prasad S Kulkarni; Elisa Marchetti; Simonetta Viviani; Musa Hassan-King; Marie-Pierre Preziosi
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

5.  Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.

Authors:  Shannon L Harris; How Tsao; Lindsey Ashton; David Goldblatt; Philip Fernsten
Journal:  Clin Vaccine Immunol       Date:  2007-02-07

6.  Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?

Authors:  Theodore F Tsai; Ray Borrow; Hanspeter E Gnehm; Bernard Vaudaux; Ulrich Heininger; Daniel Desgrandchamps; Christoph Aebi; Paul Balmer; Ronald D Pedersen; Bernard Fritzell; Claire-Anne Siegrist
Journal:  Clin Vaccine Immunol       Date:  2006-08

Review 7.  Review of meningococcal vaccines with updates on immunization in adults.

Authors:  Yorgo C Zahlanie; Moza M Hammadi; Soha T Ghanem; Ghassan S Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

8.  Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.

Authors:  Peter C Fusco; Esmé K Farley; Chun-Hsien Huang; Samuel Moore; Francis Michon
Journal:  Clin Vaccine Immunol       Date:  2007-03-21

9.  B cell mediated priming following pneumococcal colonization.

Authors:  Bradley Rabquer; Anne K Shriner; S Louise Smithson; M A Julie Westerink
Journal:  Vaccine       Date:  2006-11-28       Impact factor: 3.641

10.  Purified capsular polysaccharide of Neisseria meningitidis serogroup A as immune potentiator for antibody production.

Authors:  Tamara Menéndez; Tania Carmenate; Yoelys Cruz-Leal; Edelgis Coizeau; Evelyn Caballero; Daniel Bello; María Guirola; Anabel Alvarez; Gerardo Guillén
Journal:  Curr Microbiol       Date:  2009-09-23       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.